Breaking News Instant updates and real-time market news.

NBRV

Nabriva Therapeutics

$0.57 /

+0.0404 (+7.62%)

08:16
05/18/20
05/18
08:16
05/18/20
08:16

Nabriva Therapeutics announces publication of study on S. pneumoniae

Nabriva Therapeutics announced the publication of a study entitled, A Multicenter Evaluation of the U.S. Prevalence and Regional Variation in Macrolide Resistant S. pneumoniae from Blood or Respiratory Cultures among Adult Patients, online in the proceedings of 30th European Congress on Clinical Microbiology and Infectious Diseases. This study assessed 3,510 patients with a positive S. pneumoniae blood or respiratory culture in the ambulatory and inpatient setting at 329 hospitals across nine U.S. Census geographic regions over 12 months ending 3Q2019 to determine the prevalence and rates of macrolide resistance in S. pneumoniae. Macrolide resistance was observed in 47.3 percent of S. pneumoniae obtained from respiratory cultures, and 29.6 percent from blood cultures. Higher rates of macrolide resistance were seen among ambulatory patients (45.3 percent) as compared with inpatients. While the overall rate of macrolide resistance was 39.5 percent, regional variation occurred, ranging from 13.9 percent in the Mountain region to 54.2 percent in the West North Central region, demonstrating the importance of local epidemiology data to inform selection of empiric therapy for patients with community-acquired bacterial pneumonia. S. pneumoniae is the leading cause of community-acquired bacterial pneumonia, a lung infection and the most common type of pneumonia that occurs outside of hospitals or other health care facilities. In its 2019 Antibiotic Threats Report, the Centers for Disease Control and Prevention designated macrolide-resistant S. pneumoniae as a "Serious Threat" to patients. According to the CDC, S. pneumoniae causes 900,000 infections and 3,600 deaths annually. Joint guidelines issued by the Infectious Disease Society of America and the American Thoracic Society for the treatment of CABP recommend macrolide antibiotics only be used in geographical regions where outpatient macrolide resistance is less than 25 percent. XENLETA is a systemic pleuromutilin antibiotic for the intravenous and oral treatment of CABP in adults. XENLETA offers an effective and well tolerated empiric monotherapy for CABP with a treatment duration as short as five days and the potential to address the limitations of existing agents. XENLETA has a novel mechanism of action that targets a binding site on bacteria that is different from existing antibiotics. It has been shown to result in no cross resistance to other antibiotic classes commonly prescribed for CABP and a low potential for the development of resistance. XENLETA is also convenient for patients being treated in the hospital, transitioning treatment out of the hospital or initiating treatment in the community.

  • 19

    Jun

NBRV Nabriva Therapeutics
$0.57 /

+0.0404 (+7.62%)

04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright

TODAY'S FREE FLY STORIES

Hot Stocks
Akoustis awarded DARPA contract to advance XBAW technology » 07:28
10/27/20
10/27
07:28
10/27/20
07:28
AKTS

Akoustis

$7.97 /

-0.1 (-1.24%)

Akoustis Technologies…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AKTS Akoustis
$7.97 /

-0.1 (-1.24%)

AKTS Akoustis
$7.97 /

-0.1 (-1.24%)

08/24/20 Roth Capital
Akoustis price target raised to $12 from $10 at Roth Capital
05/04/20 Oppenheimer
Oppenheimer bullish on Akoustis as revenues ramp, management tackles milestones
05/04/20 Craig-Hallum
Akoustis longer term opportunity remains in place, says Craig-Hallum
03/26/20 Oppenheimer
Akoustis remains on track to meet 2020 sales targets, says Oppenheimer
AKTS Akoustis
$7.97 /

-0.1 (-1.24%)

  • 12
    Dec
Recommendations
HCA Healthcare price target raised to $164 from $158 at Credit Suisse » 07:28
10/27/20
10/27
07:28
10/27/20
07:28
HCA

HCA Healthcare

$135.51 /

-1.005 (-0.74%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HCA HCA Healthcare
$135.51 /

-1.005 (-0.74%)

HCA HCA Healthcare
$135.51 /

-1.005 (-0.74%)

07:12 Today Citi
HCA Healthcare price target raised to $155 from $142 at Citi
07:01 Today Mizuho
HCA Healthcare price target raised to $150 from $145 at Mizuho
06:25 Today Barclays
HCA Healthcare price target raised to $150 from $140 at Barclays
09/21/20 JPMorgan
HCA downgraded to Neutral on slowing hospital recovery at JPMorgan
HCA HCA Healthcare
$135.51 /

-1.005 (-0.74%)

HCA HCA Healthcare
$135.51 /

-1.005 (-0.74%)

HCA HCA Healthcare
$135.51 /

-1.005 (-0.74%)

HCA HCA Healthcare
$135.51 /

-1.005 (-0.74%)

Hot Stocks
Merck reports Q3 Animal Health sales up 9% to $1.2B » 07:27
10/27/20
10/27
07:27
10/27/20
07:27
MRK

Merck

$78.84 /

-1.01 (-1.26%)

Animal Health sales…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

10/23/20
Fly Intel: Pre-market Movers
10/23/20 Truist
Merck initiated with a Buy at Truist
10/16/20 JPMorgan
Merck price target raised to $105 from $98 at JPMorgan
10/08/20 Piper Sandler
Moderna regains rights to adult RSV vaccine mRNA-1172, Piper ups target to $136
MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

Hot Stocks
Brookfield, JPMorgan collaborate to power over 500 offices, branches in NY » 07:27
10/27/20
10/27
07:27
10/27/20
07:27
BEP

Brookfield Renewable Partners

$53.14 /

-0.02 (-0.04%)

, JPM

JPMorgan

$101.20 /

-2.63 (-2.53%)

JPMorgan Chase (JPM) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BEP Brookfield Renewable Partners
$53.14 /

-0.02 (-0.04%)

JPM JPMorgan
$101.20 /

-2.63 (-2.53%)

BEP Brookfield Renewable Partners
$53.14 /

-0.02 (-0.04%)

10/20/20 Credit Suisse
Brookfield Renewable Partners reinstated with a Neutral at Credit Suisse
10/08/20
Fly Intel: Top five analyst downgrades
10/08/20 Wells Fargo
Brookfield Renewable Partners downgraded to Equal Weight from Overweight at Wells Fargo
10/08/20 Wells Fargo
Brookfield Renewable downgraded to Equal Weight from Overweight at Wells Fargo
JPM JPMorgan
$101.20 /

-2.63 (-2.53%)

10/22/20 Mizuho
Square selloff on 'double whammy' a buying opportunity, says Mizuho
10/14/20 BMO Capital
JPMorgan price target raised to $119 from $117 at BMO Capital
10/14/20 Baird
JPMorgan should be bought on pullbacks, says Baird
09/21/20 Wells Fargo
Money laundering headlines creating extra headline risk for banks, says Wells
BEP Brookfield Renewable Partners
$53.14 /

-0.02 (-0.04%)

JPM JPMorgan
$101.20 /

-2.63 (-2.53%)

JPM JPMorgan
$101.20 /

-2.63 (-2.53%)

JPM JPMorgan
$101.20 /

-2.63 (-2.53%)

JPM JPMorgan
$101.20 /

-2.63 (-2.53%)

Recommendations
TriNet price target raised to $66 from $54 at Credit Suisse » 07:26
10/27/20
10/27
07:26
10/27/20
07:26
TNET

TriNet

$70.57 /

-1.92 (-2.65%)

, ADP

ADP

$145.75 /

-3.36 (-2.25%)

, PAYX

Paychex

$82.40 /

-2.54 (-2.99%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TNET TriNet
$70.57 /

-1.92 (-2.65%)

ADP ADP
$145.75 /

-3.36 (-2.25%)

PAYX Paychex
$82.40 /

-2.54 (-2.99%)

TNET TriNet
$70.57 /

-1.92 (-2.65%)

08/17/20 JPMorgan
TriNet price target raised to $82 from $65 at JPMorgan
07/28/20 Credit Suisse
TriNet price target raised to $54 from $44 at Credit Suisse
07/28/20 Stifel
TriNet price target raised to $79 from $66 at Stifel
04/29/20 Credit Suisse
TriNet price target raised to $44 from $38 at Credit Suisse
ADP ADP
$145.75 /

-3.36 (-2.25%)

09/21/20
Fly Intel: Top five analyst downgrades
09/21/20 Cowen
ADP downgraded to Market Perform on lack of catalysts at Cowen
09/21/20 Cowen
ADP downgraded to Market Perform from Outperform at Cowen
08/17/20 JPMorgan
ADP price target raised to $151 from $138 at JPMorgan
PAYX Paychex
$82.40 /

-2.54 (-2.99%)

10/15/20 Argus
Paychex price target raised to $92 from $83 at Argus
10/12/20 Barclays
Paychex price target raised to $83 from $73 at Barclays
10/08/20
Fly Intel: Top five analyst upgrades
10/08/20 Citi
Paychex upgraded to Buy from Neutral at Citi
TNET TriNet
$70.57 /

-1.92 (-2.65%)

ADP ADP
$145.75 /

-3.36 (-2.25%)

PAYX Paychex
$82.40 /

-2.54 (-2.99%)

TNET TriNet
$70.57 /

-1.92 (-2.65%)

ADP ADP
$145.75 /

-3.36 (-2.25%)

PAYX Paychex
$82.40 /

-2.54 (-2.99%)

Earnings
NeoGenomics reports Q3 EPS 4c, consensus 4c » 07:26
10/27/20
10/27
07:26
10/27/20
07:26
NEO

NeoGenomics

$41.96 /

+0.61 (+1.48%)

Reports Q3 revenue $125M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NEO NeoGenomics
$41.96 /

+0.61 (+1.48%)

NEO NeoGenomics
$41.96 /

+0.61 (+1.48%)

09/09/20 Morgan Stanley
NeoGenomics initiated with an Overweight at Morgan Stanley
08/28/20 Guggenheim
Guggenheim starts oncology testing leader NeoGenomics at Buy
08/28/20 Guggenheim
NeoGenomics initiated with a Buy at Guggenheim
07/29/20 Craig-Hallum
NeoGenomics price target raised to $42 from $36 at Craig-Hallum
NEO NeoGenomics
$41.96 /

+0.61 (+1.48%)

  • 30
    Apr
Hot Stocks
Merck reports Q3 pharmaceutical sales up 2% to $11.3B » 07:26
10/27/20
10/27
07:26
10/27/20
07:26
MRK

Merck

$78.84 /

-1.01 (-1.26%)

The increase was driven…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

10/23/20
Fly Intel: Pre-market Movers
10/23/20 Truist
Merck initiated with a Buy at Truist
10/16/20 JPMorgan
Merck price target raised to $105 from $98 at JPMorgan
10/08/20 Piper Sandler
Moderna regains rights to adult RSV vaccine mRNA-1172, Piper ups target to $136
MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

Initiation
Canada Goose initiated with a Buy at Berenberg » 07:25
10/27/20
10/27
07:25
10/27/20
07:25
GOOS

Canada Goose

$33.45 /

-2.045 (-5.76%)

Berenberg analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GOOS Canada Goose
$33.45 /

-2.045 (-5.76%)

GOOS Canada Goose
$33.45 /

-2.045 (-5.76%)

10/07/20 RBC Capital
Canada Goose price target raised to C$47 from C$43 at RBC Capital
10/07/20 RBC Capital
Canada Goose price target raised to C$47 from C$43 at RBC Capital
10/07/20 Barclays
Canada Goose price target raised to $32 from $30 at Barclays
09/30/20
Fly Intel: Top five analyst upgrades
GOOS Canada Goose
$33.45 /

-2.045 (-5.76%)

GOOS Canada Goose
$33.45 /

-2.045 (-5.76%)

GOOS Canada Goose
$33.45 /

-2.045 (-5.76%)

GOOS Canada Goose
$33.45 /

-2.045 (-5.76%)

Hot Stocks
Ceridian launches Dayforce Benefits Intelligence » 07:25
10/27/20
10/27
07:25
10/27/20
07:25
CDAY

Ceridian

$88.74 /

-3.48 (-3.77%)

Ceridian announced it is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CDAY Ceridian
$88.74 /

-3.48 (-3.77%)

CDAY Ceridian
$88.74 /

-3.48 (-3.77%)

10/23/20 Barclays
Ceridian price target raised to $95 from $76 at Barclays
10/21/20 RBC Capital
Ceridian upgraded to Outperform from Sector Perform at RBC Capital
10/21/20 RBC Capital
Ceridian upgraded to Outperform from Sector Perform at RBC Capital
08/06/20 Wells Fargo
Ceridian price target raised to $93 from $72 at Wells Fargo
CDAY Ceridian
$88.74 /

-3.48 (-3.77%)

  • 26
    Aug
  • 09
    Jun
  • 21
    May
  • 13
    Nov
CDAY Ceridian
$88.74 /

-3.48 (-3.77%)

Recommendations
Thermo Fisher price target raised to $539 from $477 at Needham » 07:25
10/27/20
10/27
07:25
10/27/20
07:25
TMO

Thermo Fisher

$482.52 /

+2.325 (+0.48%)

Needham analyst Stephen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TMO Thermo Fisher
$482.52 /

+2.325 (+0.48%)

TMO Thermo Fisher
$482.52 /

+2.325 (+0.48%)

10/22/20 SVB Leerink
Thermo Fisher price target raised to $525 from $470 at SVB Leerink
10/22/20 BTIG
Thermo Fisher price target raised to $540 from $475 at BTIG
10/22/20 Credit Suisse
Thermo Fisher price target raised to $488 from $432 at Credit Suisse
10/22/20 Baird
Thermo Fisher price target raised to $512 from $481 at Baird
TMO Thermo Fisher
$482.52 /

+2.325 (+0.48%)

TMO Thermo Fisher
$482.52 /

+2.325 (+0.48%)

TMO Thermo Fisher
$482.52 /

+2.325 (+0.48%)

TMO Thermo Fisher
$482.52 /

+2.325 (+0.48%)

Earnings
Ares Capital reports Q3 core EPS 39c, consensus 38c » 07:24
10/27/20
10/27
07:24
10/27/20
07:24
ARCC

Ares Capital

$14.02 /

-0.015 (-0.11%)

Reports Q3 NII per share…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ARCC Ares Capital
$14.02 /

-0.015 (-0.11%)

08/05/20 Citi
Ares Capital price target raised to $17 from $15 at Citi
05/07/20 Citi
Ares Capital price target raised to $15 from $13 at Citi
04/16/20 Raymond James
Ares Capital upgraded to Outperform at Raymond James on valuation
04/16/20 Raymond James
Ares Capital upgraded to Outperform from Market Perform at Raymond James
ARCC Ares Capital
$14.02 /

-0.015 (-0.11%)

ARCC Ares Capital
$14.02 /

-0.015 (-0.11%)

Hot Stocks
Merck CEO 'confident' in achieving full-year revenue growth » 07:24
10/27/20
10/27
07:24
10/27/20
07:24
MRK

Merck

$78.84 /

-1.01 (-1.26%)

"We continue to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

10/23/20
Fly Intel: Pre-market Movers
10/23/20 Truist
Merck initiated with a Buy at Truist
10/16/20 JPMorgan
Merck price target raised to $105 from $98 at JPMorgan
10/08/20 Piper Sandler
Moderna regains rights to adult RSV vaccine mRNA-1172, Piper ups target to $136
MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

Hot Stocks
Altair named official supplier for Luna Rossa Prada Pirelli team » 07:24
10/27/20
10/27
07:24
10/27/20
07:24
ALTR

Altair

$45.55 /

-1.87 (-3.94%)

Altair announced an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALTR Altair
$45.55 /

-1.87 (-3.94%)

ALTR Altair
$45.55 /

-1.87 (-3.94%)

10/14/20 Benchmark
Altair upgraded to Buy from Hold at Benchmark
09/10/20 Guggenheim
Altair upgraded to Neutral from Sell at Guggenheim
08/07/20 JPMorgan
JPMorgan no longer sees Altair underperforming, upgrades to Neutral
08/07/20 JPMorgan
Altair upgraded to Neutral from Underweight at JPMorgan
ALTR Altair
$45.55 /

-1.87 (-3.94%)

Recommendations
Amazon.com price target raised to $3,700 from $3,680 at Credit Suisse » 07:24
10/27/20
10/27
07:24
10/27/20
07:24
AMZN

Amazon.com

$3,209.39 /

+4.42 (+0.14%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$3,209.39 /

+4.42 (+0.14%)

AMZN Amazon.com
$3,209.39 /

+4.42 (+0.14%)

07:11 Today KeyBanc
Tapestry price target raised to $27 from $20 at KeyBanc
06:40 Today Deutsche Bank
Amazon.com price target raised to $4,050 from $4,000 at Deutsche Bank
10/26/20 Wedbush
Wedbush expects Amazon to report Q3 sales upside, record Q4
10/26/20 JPMorgan
JPMorgan continues to like top pick Amazon into Q3 results
AMZN Amazon.com
$3,209.39 /

+4.42 (+0.14%)

AMZN Amazon.com
$3,209.39 /

+4.42 (+0.14%)

AMZN Amazon.com
$3,209.39 /

+4.42 (+0.14%)

AMZN Amazon.com
$3,209.39 /

+4.42 (+0.14%)

AMZN Amazon.com
$3,209.39 /

+4.42 (+0.14%)

Initiation
Burlington Stores initiated with a Buy at Berenberg » 07:23
10/27/20
10/27
07:23
10/27/20
07:23
BURL

Burlington Stores

$200.33 /

-7.805 (-3.75%)

Berenberg analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BURL Burlington Stores
$200.33 /

-7.805 (-3.75%)

BURL Burlington Stores
$200.33 /

-7.805 (-3.75%)

10/07/20 Barclays
Burlington Stores price target raised to $246 from $238 at Barclays
10/01/20 Loop Capital
Burlington Stores price target raised to $240 from $225 at Loop Capital
08/28/20 Loop Capital
Burlington Stores price target lowered to $225 from $250 at Loop Capital
08/28/20 RBC Capital
Burlington Stores price target raised to $235 from $225 at RBC Capital
BURL Burlington Stores
$200.33 /

-7.805 (-3.75%)

BURL Burlington Stores
$200.33 /

-7.805 (-3.75%)

BURL Burlington Stores
$200.33 /

-7.805 (-3.75%)

Hot Stocks
Apellis, Sobi collobaroate for co-development of systemic pegcetacoplan » 07:23
10/27/20
10/27
07:23
10/27/20
07:23
APLS

Apellis

$35.92 /

+0.11 (+0.31%)

, BIOVF

Swedish Orphan Biovitrum

$0.00 /

+ (+0.00%)

Apellis Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
APLS Apellis
$35.92 /

+0.11 (+0.31%)

BIOVF Swedish Orphan Biovitrum
$0.00 /

+ (+0.00%)

APLS Apellis
$35.92 /

+0.11 (+0.31%)

09/01/20
Fly Intel: Top five analyst initiations
08/31/20 Stifel
Apellis initiated with a Buy at Stifel
07/20/20 Roth Capital
Apellis initiated with a Buy at Roth Capital
06/16/20 BTIG
Apellis initiated with a Neutral at BTIG
BIOVF Swedish Orphan Biovitrum
$0.00 /

+ (+0.00%)

07/22/20 Barclays
Swedish Orphan Biovitrum upgraded to Overweight from Equal Weight at Barclays
06/19/20 Barclays
Barclays upgrades Swedish Orphan to Equal Weight on favorable trends
06/19/20 Barclays
Swedish Orphan upgraded to Equal Weight from Underweight at Barclays
APLS Apellis
$35.92 /

+0.11 (+0.31%)

  • 09
    Jan
Recommendations
Twitter price target raised to $58 from $52 at BofA » 07:23
10/27/20
10/27
07:23
10/27/20
07:23
TWTR

Twitter

$48.99 /

-1.47 (-2.91%)

BofA analyst Justin Post…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TWTR Twitter
$48.99 /

-1.47 (-2.91%)

TWTR Twitter
$48.99 /

-1.47 (-2.91%)

06:16 Today JPMorgan
Twitter price target raised to $52 from $39 at JPMorgan
10/26/20 Wedbush
Twitter price target raised to $47 from $37.50 at Wedbush
10/26/20 Mizuho
Twitter price target raised to $45 from $40 at Mizuho
10/22/20 Argus
Snap price target raised to $50 from $30 at Argus
TWTR Twitter
$48.99 /

-1.47 (-2.91%)

TWTR Twitter
$48.99 /

-1.47 (-2.91%)

TWTR Twitter
$48.99 /

-1.47 (-2.91%)

TWTR Twitter
$48.99 /

-1.47 (-2.91%)

Hot Stocks
Casi and BioInvent enter into exclusive license agreement for BI-1206 » 07:23
10/27/20
10/27
07:23
10/27/20
07:23
CASI

Casi Pharmaceuticals

$1.80 /

+0.015 (+0.84%)

BioInvent International …

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CASI Casi Pharmaceuticals
$1.80 /

+0.015 (+0.84%)

CASI Casi Pharmaceuticals
$1.80 /

+0.015 (+0.84%)

10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
03/24/20 H.C. Wainwright
Casi Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright
  • 22
    Jul
CASI Casi Pharmaceuticals
$1.80 /

+0.015 (+0.84%)

Hot Stocks
Merck reports Q3 KEYTRUDA sales grew 21% to $3.7B » 07:22
10/27/20
10/27
07:22
10/27/20
07:22
MRK

Merck

$78.84 /

-1.01 (-1.26%)

Q3 Animal Health sales…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

10/23/20
Fly Intel: Pre-market Movers
10/23/20 Truist
Merck initiated with a Buy at Truist
10/16/20 JPMorgan
Merck price target raised to $105 from $98 at JPMorgan
10/08/20 Piper Sandler
Moderna regains rights to adult RSV vaccine mRNA-1172, Piper ups target to $136
MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

MRK Merck
$78.84 /

-1.01 (-1.26%)

Hot Stocks
Green Dot, Gig Wage launch long-term partnership » 07:22
10/27/20
10/27
07:22
10/27/20
07:22
GDOT

Green Dot

$57.71 /

-1.92 (-3.22%)

Green Dot and Gig Wage…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GDOT Green Dot
$57.71 /

-1.92 (-3.22%)

GDOT Green Dot
$57.71 /

-1.92 (-3.22%)

10/26/20 BTIG
Green Dot price target raised to $72 from $63 at BTIG
10/26/20 BTIG
Green Dot price target raised to $72 from $63 at BTIG
10/08/20 Needham
Green Dot price target raised to $70 from $62 at Needham
10/05/20 Craig-Hallum
Green Dot price target raised to $70 from $62 at Craig-Hallum
GDOT Green Dot
$57.71 /

-1.92 (-3.22%)

GDOT Green Dot
$57.71 /

-1.92 (-3.22%)

GDOT Green Dot
$57.71 /

-1.92 (-3.22%)

Initiation
Foot Locker initiated with a Buy at Berenberg » 07:21
10/27/20
10/27
07:21
10/27/20
07:21
FL

Foot Locker

$38.07 /

-1.72 (-4.32%)

Berenberg analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FL Foot Locker
$38.07 /

-1.72 (-4.32%)

FL Foot Locker
$38.07 /

-1.72 (-4.32%)

10/13/20
Fly Intel: Top five analyst upgrades
10/13/20 BofA
BofA double upgrades Foot Locker to Buy on Nike product momentum
10/13/20 BofA
Foot Locker upgraded to Buy from Underperform at BofA
10/07/20 Barclays
Barclays upgrades Retail sector to Positive, makes seven rating changes
FL Foot Locker
$38.07 /

-1.72 (-4.32%)

FL Foot Locker
$38.07 /

-1.72 (-4.32%)

FL Foot Locker
$38.07 /

-1.72 (-4.32%)

Hot Stocks
Prevail Therapeutics receives FDA Fast Track designation for PR001 » 07:20
10/27/20
10/27
07:20
10/27/20
07:20
PRVL

Prevail Therapeutics

$10.45 /

-0.39 (-3.60%)

Prevail Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

Hot Stocks
Camtek sees Q4 revenue $42M-$44M, consensus $37.77M » 07:19
10/27/20
10/27
07:19
10/27/20
07:19
CAMT

Camtek

$17.98 /

+0.08 (+0.45%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CAMT Camtek
$17.98 /

+0.08 (+0.45%)

CAMT Camtek
$17.98 /

+0.08 (+0.45%)

10/02/20 B. Riley Securities
Camtek price target raised to $21 from $20 at B. Riley Securities
02/19/20 Needham
Camtek initiated with a Buy at Needham
CAMT Camtek
$17.98 /

+0.08 (+0.45%)

Hot Stocks
Bolder Industries to become public through GigCapital2 combination » 07:19
10/27/20
10/27
07:19
10/27/20
07:19
GIX

GigCapital2

$10.19 /

+0.01 (+0.10%)

GigCapital2, a publicly…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Recommendations
Twilio price target raised to $350 from $330 at KeyBanc » 07:19
10/27/20
10/27
07:19
10/27/20
07:19
TWLO

Twilio

/

+

KeyBanc analyst Alex…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TWLO Twilio
/

+

TWLO Twilio
/

+

07:04 Today Mizuho
Twilio price target raised to $370 from $350 at Mizuho
06:12 Today Piper Sandler
Twilio price target raised to $365 from $315 at Piper Sandler
05:47 Today Goldman Sachs
Twilio price target raised to $330 from $290 at Goldman Sachs
10/14/20 Benchmark
eGain share price may be benefiting from M&A speculation, says Benchmark
TWLO Twilio
/

+

  • 07
    Aug
TWLO Twilio
/

+

TWLO Twilio
/

+

TWLO Twilio
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.